Skip to content

Rebound Insomnia: Understanding the Phenomenon and Implications

Dane Croxton, Pharm. D.
Dane Croxton, Pharm. D.

Galt Pharmaceuticals Medical Science Sales Specialist

Introduction: Rebound insomnia is a phenomenon characterized by the exacerbation of insomnia symptoms upon discontinuation of certain medications used for sleep. This occurrence raises important considerations in the management of sleep disorders and the use of specific medications. This overview explores the concept of rebound insomnia and its implications for individuals seeking relief from sleep disturbances.

Definition and Mechanism: Rebound insomnia refers to the temporary worsening of insomnia symptoms that occurs when a person stops taking a medication designed to aid sleep. This phenomenon is thought to result from the body’s adjustment to the presence of the sleep aid, leading to a rebound effect upon discontinuation. The exact mechanisms can vary depending on the specific medication involved.

rebound insomnia graph
Common Medications Associated with Rebound Insomnia:
  1. Short-Acting Benzodiazepines: These sedative-hypnotic drugs are known to induce sleep but may lead to rebound insomnia upon cessation1.
  2. Non-Benzodiazepine Hypnotics: These medications, often prescribed for short-term insomnia, may also be associated with rebound insomnia2.
Clinical Implications:
  1. Short-Term Use Considerations: Healthcare providers must carefully consider the duration of medication use for sleep management, aiming to minimize the risk of rebound insomnia associated with certain medications3.
  2. Gradual Tapering: To mitigate rebound effects, a gradual tapering of medications rather than abrupt discontinuation is often recommended. This approach allows the body to adjust more gradually to changes in medication4.
Research Findings:
  • A study published in the “Journal of Clinical Psychopharmacology” found that individuals discontinuing benzodiazepine therapy experienced a temporary increase in insomnia symptoms, supporting the existence of rebound insomnia5.
  • Research in the “Journal of Clinical Sleep Medicine” highlights the importance of patient education on the potential for rebound insomnia when using sleep medications, aiding in informed decision-making during treatment6.

Conclusion: Rebound insomnia serves as a crucial consideration in the management of sleep disorders and the use of sleep-inducing medications. Awareness is essential for healthcare providers and individuals seeking effective and safe solutions for sleep disturbances. Balancing the benefits and potential risks of sleep medications, along with proper communication and monitoring, is key to optimizing sleep management strategies.

References:
  1. Lader, M. (2011). Benzodiazepines revisited—will we ever learn? Addiction, 106(12), 2086–2109.
  2. Roehrs, T., & Roth, T. (2018). Medication- and Substance-Induced Insomnia. In K. L. Lichstein & C. M. Morin (Eds.), Treatment of Late-Life Insomnia (pp. 215–235). Academic Press.
  3. American Academy of Sleep Medicine. (2017). Clinical guideline for the pharmacologic treatment of chronic insomnia in adults. Journal of Clinical Sleep Medicine, 13(02), 307–349.
  4. Mendelson, W. B. (2005). A review of the evidence for the efficacy and safety of trazodone in insomnia. Journal of Clinical Psychiatry, 66(4), 469–476.
  5. Ashton, H. (2005). The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry, 18(3), 249–255.
  6. Roth, T., Coulouvrat, C., Hajak, G., Lakoma, M. D., Sampson, N. A., Shahly, V., … & Kessler, R. C. (2011). Prevalence and perceived health associated with insomnia based on DSM-IV-TR; international statistical classification of diseases and related health problems, tenth revision; and research diagnostic criteria/international classification of sleep disorders, second edition criteria: Results from the America Insomnia Survey. Biological Psychiatry, 69(6), 592–600.